Covid-19 vaccine maker Moderna designed its vaccine against the novel coronavirus in just two days.
On Jan. 11, Chinese authorities shared the genetic sequence of the novel coronavirus, according to Moderna's website.
Two days later, on Jan. 13, the National Institutes of Health and Moderna’s infectious disease research team finalized the sequence for mRNA-1273, the formal name of the company's Covid-19 vaccine.
The company then went on to formulate a clinical batch, according to a company spokesperson.
Moderna announced it intends to apply today to the US Food and Drug Administration for authorization of its Covid-19 vaccine.
The company will ask the FDA to review an expanded data set showing the vaccine is 94.1% effective at preventing Covid-19 and 100% effective at preventing severe cases of the disease.